TMT Newswire > GlobeNewswire
MIMEDX Announces Third Quarter 2024 Operating and Financial Results

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter

Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively

Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales

Raises 2024 Net Sales Growth Expectations to the High Single-Digits

Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET

MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX” or the "Company”), today announced operating and financial results for the third quarter 2024.

Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-over-year and an Adjusted EBITDA margin of 22%, both compared to tough comparisons in the third quarter of 2023. During the quarter, we strengthened our commercial organization, filling roles throughout the country, and continued to execute on our strategic priorities, which I believe will put us in the best position to lead this space over the long term. This performance, along with the associated free cash flow generation, demonstrates the strength of our Company even as we weather reimbursement-related market disruption. As a result, we now expect our 2024 net sales growth will be on the upper end of our prior stated guidance range of mid-to-high single-digits."

Mr. Capper continued, "During the quarter, we continued conversations with CMS, lawmakers and the MACs, leaving us optimistic that change is coming to address the runaway Medicare spend in the private office and associated care settings, which is now over $1 billion per month.   As we have known for some time, and The New York Times recently pointed out, the potential for placental tissue products is enormous. Our unwavering commitment to research and evidence production designed to support expanded utilization of our products puts us in an advantageous position as more clinicians seek to incorporate placental allografts into their practices."

    
 Three Months Ended

September 30,

 Nine Months Ended

September 30,

  2024   2023   2024   2023 
Net Income$8,095  $8,534  $34,981  $4,751 
Non-GAAP Adjustments:       
Depreciation expense 580   653   1,715   2,054 
Amortization of intangible assets 575   190   1,336   570 
Interest (income) expense, net (278)  1,680   1,409   4,864 
Income tax provision 3,541   591   11,485   569 
Share-based compensation 3,810   4,389   12,240   12,793 
Investigation, restatement and related expenses 649   (38)  (8,741)  4,652 
Impairment of intangible assets 298   -   352   - 
Transaction related expenses 95   -   651   - 
Strategic legal and regulatory expenses 1,035   -   1,666   - 
Expenses related to disbanding of Regenerative Medicine Business Unit (217)  208   (421)  5,599 
Reorganization expenses -   1,412   -   1,412 
Adjusted EBITDA$18,183  $17,619  $56,673  $37,264 
Adjusted EBITDA margin 21.6%  21.6%  22.1%  15.9%
                
                
Third Quarter 2024 Results Discussion1

Net Sales

MIMEDX reported net sales for the three months ended September 30, 2024, of $84 million, compared to $82 million for the three months ended September 30, 2023, an increase of 3%. The increase was primarily driven by growing contributions from its AMNIOEFFECT® and EPIEFFECT® products and initial contributions associated with sales of our recently launched HELIOGEN® product, partially offset by commercial challenges associated with recent turnover of certain of our sales team and customers, declines in sales of AXIOFILL® and the conclusion of sales of our dental product during the third quarter 2023.

Gross Profit and Margin

Gross profit for the three months ended September 30, 2024, was $69 million, an increase of $2 million as compared to the prior year period. Gross margin for the three months ended September 30, 2024 was 81.8%, compared to 81.9% in the prior year period. While third quarter 2024 gross margin was negatively impacted by the amortization of distribution rights stemming from the TELA Bio, Inc. and Regenity Biosciences agreements entered into during the first quarter of 2024, this impact was offset by favorable product mix and continued execution on improvements in manufacturing scale up, including reductions in scrap and improvements in yield.

Operating Expenses

Selling, general and administrative ("SG&A") expenses for the three months ended September 30, 2024, were $54 million compared to $53 million for the three months ended September 30, 2023. The increase in SG&A was driven by year-over-year increases in compensation related to higher salary and benefit costs from merit raises, promotions, as well as commissions driven by increases in sales volumes and proportionally higher sales through sales agents. Incremental spend from legal and regulatory disputes in the current period also contributed to the increase.

Research and development ("R&D") expenses for the three months ended September 30, 2024, were $3 million compared to $3 million for the three months ended September 30, 2023. R&D spend in the quarter was driven, in part, by the randomized controlled trial for EPIEFFECT and ongoing investments in the development of future products in our pipeline.

Investigation, restatement and related expense for the three months ended September 30, 2024, was $1 million compared to an immaterial benefit for the three months ended September 30, 2023. The benefit in the third quarter 2023 resulted from various settlements, including those with former officers and other matters.

Net income from continuing operations for the three months ended September 30, 2024 was $8 million compared to $9 million for the three months ended September 30, 2023.

Cash and Cash Equivalents

As of September 30, 2024, the Company had $89 million of cash and cash equivalents compared to $82 million as of December 31, 2023. As of September 30, 2024, our cash position, net of debt on our balance sheet, was $70 million, representing a sequential increase of $20 million.

Financial Outlook

For 2024, MIMEDX expects net sales growth to be in the high single-digits as a percentage compared to 2023. 2024 Adjusted EBITDA margin is expected to be above 20% on a full year basis.

Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an adjusted EBITDA margin above 20%.

Conference Call and Webcast

MIMEDX will host a conference call and webcast to review its second quarter 2024 results on Wednesday, October 30, 2024, beginning at 4:30 p.m., Eastern Time. The call can be accessed using the following information:

Webcast: Click here

U.S. Investors: 877-407-6184

International Investors: 201-389-0877

Conference ID: 13748866

A replay of the webcast will be available for approximately 30 days on the Company's website at www.mimedx.com following the conclusion of the event.

Important Cautionary Statement

This press release includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) our 2024 and longer term financial goals and expectations for future financial results, including levels of net sales, Adjusted EBITDA, and Adjusted EBITDA margin; (iii) our expectations regarding the placental tissue market (iv) our expectations regarding Medicare spending;   and (v) continued growth in different care settings, including regarding placental allografts. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "goal,” "outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.

Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; (vi) we may alter the timing and amount of planned expenditures for research and development based on regulatory developments; (vii) Medicare spending; and (viii) changes in the size of the addressable market for our products. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:

Matt Notarianni

Investor Relations

470.304.7291

mnotarianni@mimedx.com

Selected Unaudited Financial Information

 
MiMedx Group, Inc.
Condensed Consolidated Balance Sheets
(in thousands) Unaudited
 September 30,

2024

 December 31,

2023

ASSETS   
Current assets:   
Cash and cash equivalents$88,801 $82,000
Accounts receivable, net 54,030  53,871
Inventory 24,249  21,021
Prepaid expenses 2,907  5,624
Other current assets 2,152  1,745
Total current assets 172,139  164,261
    
Property and equipment, net 6,451  6,974
Right of use asset 2,843  2,132
Deferred tax asset, net 30,636  40,777
Goodwill 19,441  19,441
Intangible assets, net 11,201  5,257
Other assets 1,180  205
Total assets$243,891 $239,047
LIABILITIES AND STOCKHOLDERS' EQUITY   
Current liabilities:   
Current portion of long term debt$1,000 $1,000
Accounts payable 6,924  9,048
Accrued compensation 20,170  22,353
Accrued expenses 8,396  9,361
Current portion of Profit Share Payments 2,860  -
Current liabilities of discontinued operations -  1,352
Other current liabilities 2,591  2,894
Total current liabilities 41,941  46,008
Long term debt, net 18,018  48,099
Other liabilities 2,924  2,223
Total liabilities$62,883 $96,330
Total stockholders' equity 181,008  142,717
Total liabilities and stockholders' equity